Synonyms
|
|
Allscripts (AEHR) Order Name
|
Prometheus Anser IFX
|
Sunrise Clinical Manager (SCM) Order Name
|
PROMETHEUS Anser IFX
|
EPIC Order Name
|
PROMETHEUS Anser IFX
|
Clinical Info
|
This test is being discontinued Please order INFLIXIMAB
Serum concentrations of IFX may vary among equally dosed patients which can ultimately affect patient outcomes. Suboptimal levels of IFX have been linked to lower response rates in IBD patients. Furthermore, some patients may develop immunogenicity to IFX by producing antibodies to Infliximab (ATI). The presence of ATI has also been associated with increased rates of infusion reactions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of IFX and ATI levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response.
The PROMETHEUS Anser VDZ test is a next generation and more sensitive quantitative monitoring assay that allows healthcare providers to measure and monitor serum VDZ and ATV levels at any time during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.
|
Specimen Type
|
Blood
|
Specimen Volume
|
2 mL serum (0.5 ml min)
|
Container
|
Gold Top Tube
|
Collection Instructions
|
Container/Tube: Gold top tube
Specimen: 2 mL serum (0.5 ml min)
Transport Temperature: Room Temperature
Stability: 7 days Room Temperature
7 Days Refrigerated
|
Transport Instructions
|
Room Temperature
|
Specimen Stability
|
7 days Room Temperature
7 Days Refrigerated
|
Methodology
|
Electrochemiluminescence Immunoassay (ECLIA)
Test Includes:
Serum Infliximab concentration (IFX) and Antibodies to Infliximab (IFX)
|
Days Performed
|
Monday - Friday
TAT = 4 days from receipt at Prometheus Lab
|
Performing Laboratory
|
Prometheus Therapeutics & Diagnostics
|
CPT
|
80145
82542
|
PDM
|
1759071
|
Result Interpretation
Serum infliximab (IFX) concentration < 1.0 ug/mL
Antibodies to infliximab (ATI) Concentration < 1.6 U/mL
This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. Prometheus Laboratories Inc. is a CAP-accredited CLIA laboratory.
|
Forms
|
|
